Amid rising threat from Russia, Pluri partners with Ukrainian blood bank to stockpile remedy for deadly radiation poisoning ...

Protalix BioTherapeutics is profitable with key pipeline momentum and strategic interest. Check out why PLX stock is a strong ...

R18, developed by Israeli biotech company Pluri, is designed to treat radiation injuries caused by mass exposure. In March ...

Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 2024 financial and operational results in a March 17 th, 2024 press ...

In a report released on April 17, Julien Richer from Kepler Capital maintained a Buy rating on PLUXEE N.V. (PLX – Research Report), with a ...

The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. Having put up ...

Protalix BioTherapeutics, Inc.’s PLX share price has surged by 8.71%, which has investors questioning if this is right time to sell.

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. The Dow Jones closed lower by ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

RVPH Reviva Pharmaceuticals Holdings, Inc.